Meeting
2023 ASCO Annual Meeting
Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC).
Authors
Sara A. Byron
Integrated Cancer Genomics Division, Translational Genomics Research Institute, Phoenix, AZ
Sara A. Byron , Jiaming Zhang , Tyler Izatt , Srishti Rajeev , George Reid , Daniel Enriquez , Bryce Turner , Yaden Santana , Danielle Vasquez , Shukmei Wong , Jonathan J. Keats , Joyce O'Shaughnessy
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Biologic Correlates
Clinical Trial Registration Number
NCT02187991
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr 1037)
DOI
10.1200/JCO.2023.41.16_suppl.1037
Abstract #
1037
Poster Bd #
258
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data.
First Author: Erika Paige Hamilton
First Author: Neal A. Fischbach
Poster
2014 ASCO Annual Meeting
Whole-exome sequencing (WES) of HER2+ metastatic breast cancer (MBC) from patients (pts) treated with prior trastuzumab (T): A correlative analysis of TBCRC003.
First Author: Nikhil Wagle
First Author: Funda Meric-Bernstam